|
1）Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007; 356: 2064-72
|
|
|
|
2）Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006; 119: 71. e1-8
|
|
|
|
|
|
3）Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-112
|
|
|
|
|
|
4）Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure 1 an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980-8
|
|
|
|
|
|
5）Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010; 25: 554-63
|
|
|
|
|
|
6）Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem. 2011; 286: 10864-75
|
|
|
|
|
|
7）Barsony J, Manigrasso MB, Xu Q, et al. Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats. Age (Dordr). 2013; 35: 271-88
|
|
|
|
|
|
8）Leung AA, Wright A, Paz V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011; 124: 1064-72
|
|
|
|
|
|
9）Sonnenblick M, Friedlandler Y. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest. 1993; 103: 601-6
|
|
|
|
|
|
10）Maesaka JK, Miyawaki N, Palaia T, et al. Renal salt wasting without cerebral disease; diagnostic value of urate determinations in hyponatremia. Kidney Int. 2007; 71: 822-6
|
|
|
|
|
|
11）Kamoi K, Toyama M, lshibashi M, et al. Hyponatremia and osmoregulation of vasopressin secretion in patients with intracranial bleeding. J Clin Endocrinol Metab. 1995; 80: 2906-11
|
|
|
|
|
|
12）Zerbe RL. The syndrome of inappropriate antidiuresis. In: Baylis PH, Padfield PL, editors. The posterior pituitary; hormone secretion in health and disease. New York: Marcel Dekker; 1985. p. 261-95
|
|
|
|
|
|
13）Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006; 119(7 Suppl 1): S36-42
|
|
|
|
|
|
14）Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005; 352: 1884-90
|
|
|
|
|
|
15）Marcialis MA, Faa V, Fanos V, et al. Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol. 2008; 23: 2267-71
|
|
|
|
|
|
16）Gupta S, Chetham TD, Lambert HJ, et al. Thirst perception and arginine vasopressin production in a kindred with an activating mutation of the type 2 vasopressin receptor; the pathophysiology of nephrogenic syndrome of inappropriate antidiuresis. Eur J Endocrinol. 2009; 161: 503-8
|
|
|
|
|
|
17）Zietse R, Zoutendijk R, Hoorn EJ, et al. Fluid, electrlyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol. 2009; 5: 193-202
|
|
|
|
|
|
18）Nielsen J, Hoffert JD, Knepper MA, et al. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus; mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci U S A. 2008; 105: 3634-9
|
|
|
|
|
|
19）Rochdi MD, Vargas GA, Carpentier E, et al. Functional characterization of vasopressin type 2 receptor substitutions(R137H/C/L)leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis; implications for treatments. Mol Pharmacol. 2010; 77: 836-45
|
|
|
|
|
|
20）Carpentier E, Greenbaum LA, Rochdi D, et al. Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol. 2012; 23: 1635-40
|
|
|
|
|
|
21）Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM. 2005; 98: 529-40
|
|
|
|
|
|
22）McGee, S, Abernethy WB 3rd, Simel DL. The rational clinical examination. Is this patient hypovolemic? JAMA. 1999; 281: 1022-9
|
|
|
|
|
|
23）土肥 薫, 伊藤正明. トルバプタン長期投与によりフロセミド減量と適切な体液管理に成功した慢性心不全の一症例. 医薬ジャーナル. 2012; 48: 723-8
|
|
|
|
|
24）Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006; 290: F273-8
|
|
|
|
|
|
25）森 建文, 伊藤貞嘉. Vaptan系薬剤の使用法. 新たな体液管理の夜明け. Fluis Management Renaissance. 2013; 3: 52-60
|
|
|
|
|
|
26）Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297: 1319-31
|
|
|
|
|
|
27）Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297: 1332-43
|
|
|
|
|
|
28）森 建文, 大場郁子, 小泉賢治, 他. トルバプタン処方例の症例報告の分析. 慢性腎臓病の9症例から学ぶトルバプタンの適応. 医薬ジャーナル. 2012; 48: 178-81
|
|
|
|
|
|
29）Ishikawa M, Kobayashi N, Sugiyama F, et al. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Int Heart J. 2013; 54: 98-106
|
|
|
|